Analysts' Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)

TipRanksMay 31 06:40 ET

Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target

MT NewswiresMay 29 07:43 ET

Mind Medicine Analyst Ratings

BenzingaMay 28 16:24 ET

Mind Medicine Analyst Ratings

BenzingaMay 24 12:08 ET

Alkermes Analyst Ratings

BenzingaMay 23 11:42 ET

Cybin Analyst Ratings

BenzingaMay 16 13:07 ET

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), MacroGenics (MGNX) and Alkermes (ALKS)

TipRanksMay 14 08:20 ET

Compass Pathways Analyst Ratings

BenzingaMay 13 05:44 ET

Buy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical Trials

TipRanksMay 11 10:55 ET

Mind Medicine Analyst Ratings

BenzingaMay 10 15:37 ET

HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35

BenzingaMay 10 15:39 ET

Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)

TipRanksMay 10 12:00 ET

Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials

TipRanksMay 10 01:18 ET

COMPASS Pathways' COMP360 Shows Promise in Mental Health: A Buy Rating Amid Positive Trial Outcomes and Strategic R&D Leadership

TipRanksMay 9 06:57 ET

Analyst Ratings For Intra-Cellular Therapies

BenzingaMay 8 16:00 ET

RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)

TipRanksMay 8 06:38 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaMay 8 05:40 ET

Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline

TipRanksMay 7 14:25 ET

GH Research Analyst Ratings

BenzingaMay 7 13:44 ET

Buy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestones

TipRanksMay 7 10:35 ET